Equibles does not estimate personal net worth.
Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ANIK alertsMichael Levitz is recorded as CFO at Anika Therapeutics, Inc. (ANIK). The newest filing on record that lists Michael Levitz as CFO at Anika Therapeutics, Inc. (ANIK) is dated April 28, 2025. Anika Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Michael Levitz resigned as Chief Financial Officer, effective June 3, 2024. Anika Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer, effective May 2, 2024. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $1,774,860 for Michael Levitz in fiscal 2024, including a base salary of $514,582. Disclosed compensation is on record for 7 fiscal years. Michael Levitz has spoken on 7 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on May 8, 2024. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Cheryl Blanchard (CEO and Board Member), Stephen (Steve) Griffin (CEO and Board Member), Stephen D. Griffin (CEO, CFO and Board Member) and 7 others.
“You acknowledge and agree that your resignations described in the above subsection (i) shall be effective as of June 3, 2024.”
“On May 8, 2024, Anika Therapeutics, Inc. (the “Company”) announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024 (the “Effective Date”), replacing Michael Levitz, who tendered his resignation on May 2, 2024”
“While I have decided to leave Anika to spend more time with my family, I am very thankful for the opportunity to have been a part of the Anika team over the last four years.”
“I will now walk you through our financial results for the second quarter of 2023.”
“I will now walk you through our financial results for the first quarter of 2023. I'd like to remind everyone that, beginning in the first quarter, veterinary sales historically reported within OA Pain Management are now included in the non-orthopedic product family for all periods presented.”
“I will now walk you through our financial results for the second quarter of 2022. Total revenue for the quarter was $39.7 million, an increase of 4% over the prior year.”
“I will now walk you through our results for the first quarter of 2021. If you would please turn to Slide 6, revenue for the first quarter of 2021 was $34.3 million, a decrease of 3% from the first quarter last year.”
Start not stated–present
Last confirmed April 28, 2025
Start not stated–2024-05-02
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Anika Therapeutics, Inc. (ANIK) | Former EVP, Chief Financial Officer and Treasurer | $514,582 | $1,774,860 |
| 2023 | Anika Therapeutics, Inc. (ANIK) | Former EVP, Chief Financial Officer and Treasurer | $496,000 | $1,651,818 |
| 2022 | Anika Therapeutics, Inc. (ANIK) | Former EVP, Chief Financial Officer and Treasurer | $474,600 | $1,826,386 |
| 2021 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | $456,400 | $1,588,856 |
| 2020 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | $173,077 | $1,857,960 |
| 2019 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | — | — |
| 2018 | Anika Therapeutics, Inc. (ANIK) | EVP, Chief Financial Officer and Treasurer | — | — |
